Exploring New Boarders With Contactless Direct Selective Laser Trabeculoplasty: Our First Results

To investigate the efficacy and safety of direct selective laser trabeculoplasty (DSLT) in reducing intraocular pressure (IOP) in patients with primary open-angle glaucoma and ocular hypertension.

The study was conducted at the University Hospital Knapschaftskrankenhaus Bochum from November 2022 to December 2022 on patients with primary open-angle glaucoma and ocular hypertension.

A prospective case series of 28 eyes of 14 patients with primary open-angle glaucoma and ocular hypertension were treated with DSLT. IOP was measured at baseline and 1 hour after the treatment, as well as at follow-up visits on 1 day and 1-month post-treatment. All adverse events and complications were recorded.

The mean IOP at baseline was 22.4 mmHg. At the 1-month follow-up visit, the mean IOP was significantly reduced to 17.3 mmHg (p < 0.05). All patients showed a reduction in IOP of at least 20% without any change in the topical glaucoma medication. There were no significant adverse events or complications reported.

DSLT is a safe and effective treatment for reducing IOP in patients with primary open-angle glaucoma and ocular hypertension. The procedure resulted in a significant reduction in IOP at the 1-month follow-up visit, with a high success rate and excellent safety profile. Longer-term randomized controlled studies are needed to establish the durability of the treatment effect and to determine the optimal treatment regimen for patients.